Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety of combining ipilimumab and
nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic
melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab
and hypofractionated radiotherapy on the cancer as compared to ipilimumab and nivolumab.